X4 PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.165 USD | +3.10% |
|
-7.54% | +38.94% |
| Mar. 21 | Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
| Mar. 21 | X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 172.3 | 104.7 | 64.41 | 120.7 | 140.3 | 195.6 | - | - |
| Enterprise Value (EV) 1 | 172.3 | 104.7 | 64.41 | 120.7 | 140.3 | 195.6 | 195.6 | 195.6 |
| P/E ratio | -2.31 x | -2.08 x | -0.57 x | -0.65 x | -1.47 x | -2.58 x | -2.6 x | -4.66 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 34.9 x | - | - | - | 6.81 x | 3.31 x | 1.86 x |
| EV / Revenue | - | 34.9 x | - | - | - | 6.81 x | 3.31 x | 1.86 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -3.57 x | -1.74 x | -0.9 x | -1.56 x | - | -8.51 x | -2.17 x | -2.39 x |
| FCF Yield | -28% | -57.5% | -111% | -64% | - | -11.8% | -46% | -41.9% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,103 | 16,287 | 28,127 | 121,535 | 167,291 | 167,938 | - | - |
| Reference price 2 | 10.70 | 6.430 | 2.290 | 0.9930 | 0.8385 | 1.165 | 1.165 | 1.165 |
| Announcement Date | 3/12/20 | 3/4/21 | 3/17/22 | 3/21/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 3 | - | - | - | 28.72 | 59.14 | 105.4 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.7 | -59.87 | -75.35 | -87.57 | -107.5 | -105.7 | -103.7 | -67.81 |
| Operating Margin | - | -1,995.8% | - | - | - | -368.01% | -175.39% | -64.35% |
| Earnings before Tax (EBT) 1 | -52.81 | -61.98 | -88.68 | -93.84 | -101.1 | -94.29 | -106.6 | -68.94 |
| Net income 1 | -53.4 | -62.13 | -102.6 | -96.41 | -101.2 | -94.29 | -106.6 | -71.48 |
| Net margin | - | -2,071.03% | - | - | - | -328.35% | -180.23% | -67.83% |
| EPS 2 | -4.630 | -3.090 | -3.990 | -1.520 | -0.5700 | -0.4514 | -0.4486 | -0.2500 |
| Free Cash Flow 1 | -48.23 | -60.18 | -71.52 | -77.2 | - | -23 | -90 | -82 |
| FCF margin | - | -2,006% | - | - | - | -80.09% | -152.17% | -77.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/4/21 | 3/17/22 | 3/21/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | 15.47 | 3.179 | 10.03 | 12.29 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -19.12 | -19.3 | -21.27 | -20.57 | -20.15 | -25.58 | -29.3 | -25.8 | -27.21 | -25.2 | -29.25 | -16.4 | -32.21 | -27.85 | -35.24 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | -106.02% | -1,013.27% | -277.57% | -286.69% |
| Earnings before Tax (EBT) 1 | -20.17 | -30.2 | -21.94 | -21.21 | -21.6 | -29.09 | -24.02 | -55.7 | -2.279 | -19.1 | -29.7 | -2.665 | -33.08 | -28.85 | -35.54 |
| Net income 1 | -20.18 | -35.91 | -24.22 | -21.21 | -21.87 | -29.1 | -24.02 | -55.71 | -2.305 | -19.13 | -29.7 | -2.667 | -33.09 | -28.85 | -35.54 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | -17.24% | -1,040.85% | -287.55% | -289.13% |
| EPS 2 | -0.7600 | -1.240 | -0.7200 | -0.6000 | -0.2600 | -0.2900 | -0.1600 | -0.3300 | -0.0100 | -0.1000 | -0.1543 | -0.0329 | -0.1614 | -0.1429 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/17/22 | 5/12/22 | 8/4/22 | 11/3/22 | 3/21/23 | 5/4/23 | 8/10/23 | 11/9/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -48.2 | -60.2 | -71.5 | -77.2 | - | -23 | -90 | -82 |
| ROE (net income / shareholders' equity) | - | -61.5% | -150% | -127% | -162% | - | - | 160% |
| ROA (Net income/ Total Assets) | - | -43.8% | -85.5% | -70.7% | -66.8% | -153% | -19.8% | 63.8% |
| Assets 1 | - | 141.8 | 120 | 136.4 | 151.4 | 61.79 | 538.3 | -112 |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | -2.930 | -2.750 | -1.210 | -0.5400 | -0.3200 | 0.0200 | 0.3400 |
| Capex 1 | - | 1.36 | 0.62 | 0.1 | - | - | 1 | 1 |
| Capex / Sales | - | 45.4% | - | - | - | - | 1.69% | 0.95% |
| Announcement Date | 3/12/20 | 3/4/21 | 3/17/22 | 3/21/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.165
USD
Average target price
3.554
USD
Spread / Average Target
+205.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.94% | 196M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- XFOR Stock
- Financials X4 Pharmaceuticals, Inc.
